2024
DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance
Conway K, Edmiston S, Vondras A, Reiner A, Corcoran D, Shen R, Parrish E, Hao H, Lin L, Kenney J, Ilelaboye G, Kostrzewa C, Kuan P, Busam K, Lezcano C, Lee T, Hernando E, Googe P, Ollila D, Moschos S, Gorlov I, Amos C, Ernstoff M, Cust A, Wilmott J, Scolyer R, Mann G, Vergara I, Ko J, Rees J, Yan S, Nagore E, Bosenberg M, Rothberg B, Osman I, Lee J, Saenger Y, Bogner P, Thompson C, Gerstenblith M, Holmen S, Funchain P, Brunsgaard E, Depcik-Smith N, Luo L, Boyce T, Orlow I, Begg C, Berwick M, Thomas N, Berwick M, Luo L, Boyce T, Reynolds A, Wiggins C, Thomas N, Conway K, Edmiston S, Ollila D, Hao H, Parrish E, Googe P, Moschos S, Corcoran D, Vondras A, Tsai Y, Lin L, Shen R, Begg C, Arora A, Seshan V, Reiner A, Kostrzewa C, Busam K, Orlow I, Lezcano C, Kenney J, Sadeghi K, O'Connell K, Ilelaboye G, Parmar H, Leong S, Corrales S, Scolyer R, Cust A, Wilmott J, Mann G, Shang P, Burke H, Ferguson P, Jakrot V, Lee T, Hernando E, Osman I, Hanniford D, Argibay D, Moran U, Heguy A, Ramaswami S, Amos C, Gorlov I, Zhu D, Ernstoff M, Bogner P, Lee J, Rees J, Yan S, Gerstenblith M, Thompson C, Ko J, Funchain P, Ngo P, Bosenberg M, Gould Rothberg B, Panse G, Saenger Y, Fullerton B, Holmen S, Colman H, Brunsgaard E, Wada D, Nagore E, Manrique-Silva E, Requena C, Traves V, Millan-Esteban D, Rainka M. DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance. JCO Precision Oncology 2024, 8: e2400375. PMID: 39509669, PMCID: PMC11737429, DOI: 10.1200/po-24-00375.Peer-Reviewed Original ResearchConceptsAmerican Joint Committee on CancerCpG island methylator phenotypePrimary melanomaBreslow thicknessMethylation classClinicopathological characteristicsN stageRisk of melanoma-related deathLow methylationStage IIRetrospective case-control studyCutaneous primary melanomaHigher AJCC stagePrimary cutaneous melanomaHigher N stageMelanoma-related deathDNA methylation classDied of melanomaMitotic indexCase-control studyIII patientsClinicopathological factorsCpG island hypermethylationPrognostic significanceAJCC stageCorrelation of eTILs with recurrence free survival (RFS) in stage IIB-IIIA melanoma and use as biomarker for stratification for clinical trials.
Aung T, Zhang C, Espinoza G, Leung L, Moon J, Horst B, Ferringer T, Nastiuk K, Rimm D, Saenger Y. Correlation of eTILs with recurrence free survival (RFS) in stage IIB-IIIA melanoma and use as biomarker for stratification for clinical trials. Journal Of Clinical Oncology 2024, 42: 9567-9567. DOI: 10.1200/jco.2024.42.16_suppl.9567.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesRecurrence free survivalAmerican Joint Committee on CancerFree survivalInfiltrating lymphocytesRetrospective cohortClinical trialsQuantify tumor-infiltrating lymphocytesStage II-III melanomaTumor-infiltrating lymphocytes groupDiagnostic slidesIIb-IIIaRoswell Park Comprehensive Cancer CenterEarly-stage melanoma patientsCox modelStage IIB-IIICAdjuvant clinical trialsKaplan-Meier curvesMultivariate Cox modelUnivariate Cox modelCox proportional hazards modelsClinical pathological featuresGeisinger Medical CenterProportional hazards modelClinical trial design
2023
Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy
Panian J, Saidian A, Hakimi K, Ajmera A, Anderson W, Barata P, Berg S, Signoretti S, Chang S, D’Andrea V, George D, Dzimitrowicz H, Zarif T, Emamekhoo H, Gross E, Kilari D, Lam E, Lashgari I, Psutka S, Rauterkus G, Shabaik A, Thapa B, Wang L, Weise N, Yim K, Zhang T, Derweesh I, McKay R. Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy. The Oncologist 2023, 29: 870-877. PMID: 37368355, PMCID: PMC11448883, DOI: 10.1093/oncolo/oyad166.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaRenal cell carcinomaProgression-free survivalAmerican Joint Committee on CancerAdvanced renal cell carcinomaCytoreductive nephrectomyPathological outcomesCell carcinomaMedian progression-free survivalPathologic outcomes of patientsCorrelated to clinical variablesRetrospective study of patientsEra of immunotherapySurgical pathology outcomeMedian Follow-UpResponse Evaluation CriteriaKaplan-Meier methodOutcomes of patientsTime of surgeryFraction of patientsStudy of patientsStandard of careIO monotherapyPathological downstagingCell histology
2018
Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma
Liu C, Cheng H, Jin K, Guo M, Lu Y, Wang Z, Yang C, Long J, Ni Q, Yu X, Luo G. Application of the Eighth Edition of the American Joint Committee on Cancer Staging for Pancreatic Adenocarcinoma. Pancreas 2018, 47: 742-747. PMID: 29851752, DOI: 10.1097/mpa.0000000000001073.Peer-Reviewed Original ResearchConceptsAmerican Joint Committee on CancerAmerican Joint Committee on Cancer stageTumor resectionPancreatic cancerEighth editionAmerican Joint Committee on Cancer eighth editionAmerican Joint Committee on Cancer seventh editionStage classificationLymph node involvementEnd Results registrySeventh editionPrognosis to patientsNode involvementTumor diameterPositive nodesInstitutional seriesPancreatic adenocarcinomaCancer stageStage distributionSurvival curvesPatientsSurvival analysisTumorStatistical differenceCancer
2013
Transcriptome Profiling Identifies HMGA2 as a Biomarker of Melanoma Progression and Prognosis
Raskin L, Fullen D, Giordano T, Thomas D, Frohm M, B. K, Ahn J, Mukherjee B, Johnson T, Gruber S. Transcriptome Profiling Identifies HMGA2 as a Biomarker of Melanoma Progression and Prognosis. Journal Of Investigative Dermatology 2013, 133: 2585-2592. PMID: 23633021, PMCID: PMC4267221, DOI: 10.1038/jid.2013.197.Peer-Reviewed Original ResearchConceptsAmerican Joint Committee on CancerOverall survivalTissue microarrayPrimary melanomaMelanoma pathogenesisMelanoma progressionAssociated with disease-free survivalAnalysis of tissue microarraysMetastases-free survivalDisease-free survivalHMGA2 overexpressionCox proportional hazards regression modelsLog-rank testPredictors of survivalProportional hazards regression modelsHazards regression modelsBRAF/NRAS mutationsPrimary tumorPrognostic featuresMelanoma metastasesClinicopathological characteristicsReal-time PCRGenetic alterationsAQUA analysisMelanoma development
2012
TNM staging of colorectal carcinoma: issues and caveats
Shia J, Klimstra D, Bagci P, Basturk O, Adsay N. TNM staging of colorectal carcinoma: issues and caveats. Seminars In Diagnostic Pathology 2012, 29: 142-153. PMID: 23062421, DOI: 10.1053/j.semdp.2012.02.001.Peer-Reviewed Original ResearchConceptsPathologic interpretationAmerican Joint Committee on CancerTreatment of colorectal carcinomaHistopathological prognostic factorsTNM staging systemInternational Cancer ControlStaging parametersAnal carcinomaPrognostic factorsResected specimenSerosal involvementRadial marginRectal resectionTumor differentiationStaging systemColorectal carcinomaCancer controlMicroscopic findingsTNMTrue invasionCarcinomaTumor
2011
Prospective impact of tumor grade assessment in biopsies on tumor stage and prognostic grouping in gastroesophageal adenocarcinoma
Dikken J, Coit D, Klimstra D, Rizk N, van Grieken N, Ilson D, Tang L. Prospective impact of tumor grade assessment in biopsies on tumor stage and prognostic grouping in gastroesophageal adenocarcinoma. Cancer 2011, 118: 349-357. PMID: 21720993, DOI: 10.1002/cncr.26301.Peer-Reviewed Original ResearchConceptsAmerican Joint Committee on CancerTumor grade assessmentPreoperative tumor gradeTumor gradeNeoadjuvant therapyStage groupT1-T2N0Esophageal adenocarcinomaGRADE assessmentLow stage groupPostoperative tumor gradeLymph node-negativeEarly stage adenocarcinomaExclusion of tumorsHigh stage groupEarly stage tumorsNode-negativeGastroesophageal adenocarcinomaStage adenocarcinomaPrognostic groupsPreoperative stagingStage tumorsTumor stagePreoperative gradeHistopathological gradeA new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: Creation and rationale for inclusion of tumor (T) characteristics
Farasat S, Yu S, Neel V, Nehal K, Lardaro T, Mihm M, Byrd D, Balch C, Califano J, Chuang A, Sharfman W, Shah J, Nghiem P, Otley C, Tufaro A, Johnson T, Sober A, Liégeois N. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: Creation and rationale for inclusion of tumor (T) characteristics. Journal Of The American Academy Of Dermatology 2011, 64: 1051-1059. PMID: 21255868, PMCID: PMC4659347, DOI: 10.1016/j.jaad.2010.08.033.Peer-Reviewed Original ResearchConceptsAmerican Joint Committee on CancerCutaneous squamous cell carcinomaAmerican Joint Committee on Cancer staging systemSquamous cell carcinomaStaging systemT classificationCell carcinomaStaging ManualAmerican Joint Committee on Cancer Staging ManualAmerican Joint Committee on Cancer Cancer Staging ManualIncidence of cutaneous squamous cell carcinomaMultivariate analysisPurposes of stagingCancer staging systemHigh-risk featuresCancer Staging ManualNonmelanoma skin cancerProspective outcome trialsTumor thicknessTumor characteristicsTumor diameterPerineural invasionAdvanced diseaseSurgical treatmentStaging criteria
2008
Is Nonsmall Cell Type High-grade Neuroendocrine Carcinoma of the Tubular Gastrointestinal Tract a Distinct Disease Entity?
Shia J, Tang L, Weiser M, Brenner B, Adsay N, Stelow E, Saltz L, Qin J, Landmann R, Leonard G, Dhall D, Temple L, Guillem J, Paty P, Kelsen D, Wong W, Klimstra D. Is Nonsmall Cell Type High-grade Neuroendocrine Carcinoma of the Tubular Gastrointestinal Tract a Distinct Disease Entity? The American Journal Of Surgical Pathology 2008, 32: 719-731. PMID: 18360283, DOI: 10.1097/pas.0b013e318159371c.Peer-Reviewed Original ResearchConceptsHigh-grade neuroendocrine carcinomaSmall cell carcinomaCell neuroendocrine carcinomaNeuroendocrine carcinomaSmall cell typeCell carcinomaHistological subtypesNeuroendocrine markersGI tractPositive immunoreactivityWorld Health Organization/International AssociationAmerican Joint Committee on CancerCell typesPulmonary small cell carcinomaNo significant survival differenceAdenocarcinoma-neuroendocrine carcinomaPulmonary neuroendocrine tumorsDisease-specific survivalGI tract tumorsSignificant survival differenceGastrointestinal (GI) tractFocal intracytoplasmic mucinTubular gastrointestinal tractPulmonary counterpartImmunophenotypic spectrum
2007
Pancreatic Adenocarcinoma: The Actual 5-Year Survivors
Ferrone C, Brennan M, Gonen M, Coit D, Fong Y, Chung S, Tang L, Klimstra D, Allen P. Pancreatic Adenocarcinoma: The Actual 5-Year Survivors. Journal Of Gastrointestinal Surgery 2007, 12: 701-706. PMID: 18027062, DOI: 10.1007/s11605-007-0384-8.Peer-Reviewed Original ResearchConceptsActual 5-year survivalAmerican Joint Committee on CancerAssociated with 5-year survivalLong-term survivalNegative marginsPancreatic adenocarcinomaFactors associated with long-term survivalPredictors of long-term survivalResection of pancreatic adenocarcinomaStage IA diseaseMedian Follow-UpReports of patientsTreatment-related variablesIA diseaseRecurrent diseaseAdjuvant therapyTumor locationAJCC stagePatient agePancreatic cancerFollow-upResectionSurvival ratePatientsTumorDifferential expression of α-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance
Lin A, Weiser M, Klimstra D, Paty P, Tang L, Al-Ahmadie H, Park S, Guillem J, Temple L, Wong W, Gerald W, Shia J. Differential expression of α-methylacyl-coenzyme A racemase in colorectal carcinoma bears clinical and pathologic significance. Human Pathology 2007, 38: 850-856. PMID: 17442371, DOI: 10.1016/j.humpath.2006.12.016.Peer-Reviewed Original ResearchConceptsAlpha-methylacyl-coenzyme A racemaseAmerican Joint Committee on CancerAlpha-methylacyl-coenzyme A racemase expressionDisease-specific survivalLow-intensity stainingColorectal carcinomaLymphovascular invasionPeroxisomal beta-oxidation of branched-chain fatty acidsAlpha-methylacyl coenzyme A racemase stainingOverexpression of alpha-methylacyl coenzyme A racemasePatient outcomesPathological characteristicsAmerican Joint Committee on Cancer stagePresence of lymphovascular invasionAssociated with prostate cancer progressionModerate to strong stainingHigher American Joint Committee on CancerTumor pathological characteristicsTumor pathologic featuresPrimary colorectal carcinomaProstate cancer progressionPoor tumor differentiationBeta-oxidation of branched-chain fatty acidsRed meatImmunohistochemical expression pattern
2004
Neuroendocrine Carcinomas of the Colon and Rectum
Bernick P, Klimstra D, Shia J, Minsky B, Saltz L, Shi W, Thaler H, Guillem J, Paty P, Cohen A, Wong W. Neuroendocrine Carcinomas of the Colon and Rectum. Diseases Of The Colon & Rectum 2004, 47: 163-169. PMID: 15043285, DOI: 10.1007/s10350-003-0038-1.Peer-Reviewed Original ResearchConceptsTime of diagnosisAmerican Joint Committee on CancerNeuroendocrine carcinomaMetastatic diseaseHigh-grade neuroendocrine carcinomaDiagnosis of neuroendocrine carcinomaMedian follow-up timeMarkers of neuroendocrine differentiationStudy group of patientsCell neuroendocrine carcinomaSmall cell carcinomaAverage patient ageThree-year survivalService databaseGroup of patientsNeuron-specific enolaseMedian survivalNeuroendocrine differentiationNeuroendocrine tumorsCarcinoid tumorsCell carcinomaNeuroendocrine markersPatient ageRectal cancerNo significant difference
2000
Lymph Node Staging in Gastric Cancer: Is Location More Important Than Number?
Karpeh M, Leon L, Klimstra D, Brennan M. Lymph Node Staging in Gastric Cancer: Is Location More Important Than Number? Annals Of Surgery 2000, 232: 362-371. PMID: 10973386, PMCID: PMC1421150, DOI: 10.1097/00000658-200009000-00008.Peer-Reviewed Original ResearchConceptsAmerican Joint Committee on CancerPositive nodesMedian survivalLymph nodesGastric cancerN stageAJCC N-staging systemAmerican Joint Committee on Cancer N stageUnion Internationale Contre le CancerLymph node stagingPositive lymph nodesMetastatic lymph nodesLocation of positive nodesN staging systemKaplan-Meier methodExamined lymph nodesEstimate median survivalNorth American centersR0 resectionPrognostic influenceNode stagingAdequate stagingNode metastasisN categorySurvival rate
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply